User login
BARCELONA — Anti-tumor necrosis factor-α drugs may aid insulin resistance in rheumatoid arthritis, according to studies presented at the annual European Congress of Rheumatology.
Traditional and nontraditional risk factors, like systemic inflammation and insulin resistance, have been implicated in cardio-vascular disease in RA, said Dr. Sabrina Paolino of the University of Genova, Italy. Insulin resistance also has been shown to influence the development and progression of atherosclerotic lesions in rheumatic diseases and RA.
Dr. Paolino and colleagues compared 32 patients with active RA who were treated with either infliximab (3 mg/kg at week 0, 2, 6, and every 8 weeks thereafter) or etanercept (25 mg twice per week), with 20 RA patients not on anti-TNF-α drugs. All patients received prednisone (maximum of 7.5 mg/day) and methotrexate (10 mg/week). Subjects with frank diabetes; viral hepatitis B or C infection; any malignancy; liver or kidney disease; or endocrine or metabolic disorders, or who took medications that influence glucose metabolism were excluded.
At 24 weeks, patients on anti-TNF-α therapy had significantly greater improvement in disease activity score using 28 joint counts, the Quantitive Insulin Sensitivity Check Index, and the homeostasis model assessment of insulin resistance (HOMA) than those not on anti-TNF-α drugs. There were no differences in insulin resistance between patients on etanercept and those on infliximab.
In a poster presented at the Congress, insulin resistance as calculated on the HOMA index and hemoglobin A1c were significantly lower in 16 nondiabetic RA patients after 1 year of anti-TNF-α therapy. No significant changes occurred during follow-up on dietary questionnaires, physical activity levels, anthropometric measurements, body mass index, or fat mass to confound the anti-TNF-α and insulin resistance link. Cholesterol and triglyceride levels did not change, said Dr. Sigrid Talaverano and associates at the University Hospital of the Canary Islands, La Cuesta, Spain.
BARCELONA — Anti-tumor necrosis factor-α drugs may aid insulin resistance in rheumatoid arthritis, according to studies presented at the annual European Congress of Rheumatology.
Traditional and nontraditional risk factors, like systemic inflammation and insulin resistance, have been implicated in cardio-vascular disease in RA, said Dr. Sabrina Paolino of the University of Genova, Italy. Insulin resistance also has been shown to influence the development and progression of atherosclerotic lesions in rheumatic diseases and RA.
Dr. Paolino and colleagues compared 32 patients with active RA who were treated with either infliximab (3 mg/kg at week 0, 2, 6, and every 8 weeks thereafter) or etanercept (25 mg twice per week), with 20 RA patients not on anti-TNF-α drugs. All patients received prednisone (maximum of 7.5 mg/day) and methotrexate (10 mg/week). Subjects with frank diabetes; viral hepatitis B or C infection; any malignancy; liver or kidney disease; or endocrine or metabolic disorders, or who took medications that influence glucose metabolism were excluded.
At 24 weeks, patients on anti-TNF-α therapy had significantly greater improvement in disease activity score using 28 joint counts, the Quantitive Insulin Sensitivity Check Index, and the homeostasis model assessment of insulin resistance (HOMA) than those not on anti-TNF-α drugs. There were no differences in insulin resistance between patients on etanercept and those on infliximab.
In a poster presented at the Congress, insulin resistance as calculated on the HOMA index and hemoglobin A1c were significantly lower in 16 nondiabetic RA patients after 1 year of anti-TNF-α therapy. No significant changes occurred during follow-up on dietary questionnaires, physical activity levels, anthropometric measurements, body mass index, or fat mass to confound the anti-TNF-α and insulin resistance link. Cholesterol and triglyceride levels did not change, said Dr. Sigrid Talaverano and associates at the University Hospital of the Canary Islands, La Cuesta, Spain.
BARCELONA — Anti-tumor necrosis factor-α drugs may aid insulin resistance in rheumatoid arthritis, according to studies presented at the annual European Congress of Rheumatology.
Traditional and nontraditional risk factors, like systemic inflammation and insulin resistance, have been implicated in cardio-vascular disease in RA, said Dr. Sabrina Paolino of the University of Genova, Italy. Insulin resistance also has been shown to influence the development and progression of atherosclerotic lesions in rheumatic diseases and RA.
Dr. Paolino and colleagues compared 32 patients with active RA who were treated with either infliximab (3 mg/kg at week 0, 2, 6, and every 8 weeks thereafter) or etanercept (25 mg twice per week), with 20 RA patients not on anti-TNF-α drugs. All patients received prednisone (maximum of 7.5 mg/day) and methotrexate (10 mg/week). Subjects with frank diabetes; viral hepatitis B or C infection; any malignancy; liver or kidney disease; or endocrine or metabolic disorders, or who took medications that influence glucose metabolism were excluded.
At 24 weeks, patients on anti-TNF-α therapy had significantly greater improvement in disease activity score using 28 joint counts, the Quantitive Insulin Sensitivity Check Index, and the homeostasis model assessment of insulin resistance (HOMA) than those not on anti-TNF-α drugs. There were no differences in insulin resistance between patients on etanercept and those on infliximab.
In a poster presented at the Congress, insulin resistance as calculated on the HOMA index and hemoglobin A1c were significantly lower in 16 nondiabetic RA patients after 1 year of anti-TNF-α therapy. No significant changes occurred during follow-up on dietary questionnaires, physical activity levels, anthropometric measurements, body mass index, or fat mass to confound the anti-TNF-α and insulin resistance link. Cholesterol and triglyceride levels did not change, said Dr. Sigrid Talaverano and associates at the University Hospital of the Canary Islands, La Cuesta, Spain.